Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX · NASDAQ Global Market
+$0.00 today
Vol 1.50M · Avg 0.54M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.4%
avg 36.8%
ROIC
-38.6%
avg 36.8%
ROA
-32.0%
avg -157.7%
Analysis
ROA is currently the strongest return metric at -32.0% versus its period average of -157.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Claire Mazumdar Clemon | Chief Executive Officer & Director | $927,688.00 | — | 36 | $377,152.00 | 0.69% |
Ivan Hyep | CFO & Treasurer | $915,375.00 | — | 41 | $154,555.00 | 0.28% |
Ryan Cohlhepp | President, Chief Operating Officer & Director | $858,400.00 | — | 49 | $196,141.00 | 0.36% |
David Raben | Chief Medical Officer | $709,164.00 | — | 62 | $60,786.00 | 0.11% |
Angela Windt | Vice President & Head of Regulatory Affairs | — | — | — | — | — |
Jean-Paul Rodrique | Senior Vice President & Global Head of Quality Assurance | — | — | — | — | — |
Jenna Cohen | Chief Corporate Affairs Officer | — | — | — | — | — |
Tanya Green | Chief Development Officer | — | — | — | — | — |
Gary Bostanxhi | Vice President of Finance & Controller | — | — | — | — | — |
Rachel Salazar | SVP of R&D Strategy and Operations | — | — | — | — | — |
Lara S. Meisner | Chief Legal Officer, Compliance Officer & Corporate Secretary | — | — | 54 | $90,000.00 | 0.16% |
Pauline Dufresne | Chief People Officer | — | — | — | — | — |
Rachel Frank | Vice President of Investor Relations and Corporate Communications | — | — | — | — | — |
Sathish Hasige | Senior Vice President and Head of Technical Operations & Supply Chain | — | — | — | — | — |
Jeltje Schulten | Senior Vice President of Clinical & Medical Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$4.80M
Sells
56
$9.00M
Net Sentiment
$4.20M
Net selling
Most Active
Cohlhepp Ryan
22 transactions
1–10 of 58
Analysis
Insiders reported 2 buys worth $4.80M and 56 sells worth $9.00M over the last 12 months. That adds up to net selling of $4.20M. Cohlhepp Ryan was the most active insider with 22 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.56B
Septerna, Inc.
NASDAQ:SEPN
$1.56B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.44B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.12B
Savara Inc.
NASDAQ:SVRA
$1.11B
Kura Oncology, Inc.
NASDAQ:KURA
$852.23M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$848.92M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$734.91M
Prime Medicine, Inc.
NASDAQ:PRME
$562.62M
ProKidney Corp.
NASDAQ:PROK
$261.51M
Who manages BCAX?
Bicara Therapeutics Inc. Common Stock (BCAX) lists 15 active executives. The top listed executive is Claire Mazumdar Clemon, Chief Executive Officer & Director.
Are BCAX insiders buying or selling?
Recent insider activity shows net buying of $52.99M.
Explore More
Continue the stock analysis
Jump to another research area for this company.